Elizabeth currently serves as Chief Financial Officer for Mirror Biologics, Inc., a private clinical stage oncology company. She previously served as Chief Financial Officer for several other public and private biopharma companies, where she was successful in helping achieve public listings for commercial-stage Scilex Holding, Inc. through a SPAC merger, Altimmune, Inc. via merger with a public company, and an IPO for Cancer Genetics, Inc. Elizabeth began her career serving in senior and executive level positions for 18 years at BASF (Knoll) Pharmaceuticals, Hoffmann-La Roche, and Merck & Co. Her major pharma executive level experience includes M&A, licensing, business development and finance. She received a B.A., magna cum laude in Spanish and Mathematics Education from Marshall University and an MBA from Rutgers University.